GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (BSP:REGN34) » Definitions » Short Interest

Regeneron Pharmaceuticals (BSP:REGN34) Short Interest


View and export this data going back to 2019. Start your Free Trial

What is Regeneron Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Regeneron Pharmaceuticals's Short Interest

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regeneron Pharmaceuticals's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Short Interest falls into.


Regeneron Pharmaceuticals (BSP:REGN34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (BSP:REGN34) » Definitions » Short Interest
Comparable Companies
VRTX MRNA BNTX ALNY BGNE BMRN RPRX SRPT INCY UTHR OCSE:NOVO B ASX:CSL XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX OCSE:GMAB SHSE:603392 SZSE:300122 XKRX:028300
Traded in Other Exchanges
REGN:USA REGN:Mexico RGO:Germany
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Website
https://www.regeneron.com
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Regeneron Pharmaceuticals (BSP:REGN34) Headlines

No Headlines